The U.S. Food and Drug Administration today approved Tembexa (brincidofovir) to treat smallpox.
Authorization granted without human testing.
Tembexa received priority review, fast track and orphan drug designations.
Tembexa was developed in conjunction with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). FDA granted approval of Tembexa to Chimerix Inc.